Abatacept
A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.
Áreas Terapêuticas
Mecanismo de Ação
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
Yes, Abatacept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201823. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="abatacept"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/abatacept/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/abatacept/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/abatacept/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="abatacept"></drugfyi-drug>